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1. Introduction
Type I diabetes (insulin-dependent diabetes mellitus, IDDM) is a chronic autoimmune disease
caused by the selective destruction of insulin-producing β-cells in the pancreatic islets of
Langerhans, which results in severe insulin deficiency. Insufficient circulating levels of insulin
lead to potentially fatal metabolic dysfunction. Although the exact mechanism of islet cell
destruction is unclear, a T-cell-mediated autoimmune process seems to be the most likely
explanation. Other factors, genetic and environmental, are likely contributing causes, but have
not been fully identified as of yet.
Although whole pancreas transplantation has been considered as a therapeutic option for
selected patients with IDDM, most individuals with the disease are not likely candidates for
this therapy. Since the discovery of insulin in the 1920’s, the main therapeutic approach to
treating IDDM patients has been insulin replacement [1]. The standard of care for most patients
with Type 1 diabetes is based on exogenous insulin therapy delivered through several daily
injections. Despite great improvements in insulin delivery systems seen in the last two decades,
it’s still difficult to provide the precise amount of insulin that is required by the patient at any
given time. This results in hypo- and hyperglycemic episodes, potentially leading to cell
damage in many tissues, ultimately resulting in the development of severe long-term compli‐
cations. Therefore, insulin delivery systems which can quickly and continuously respond to
constantly changing physiological needs of the organism by adjusting the amount of insulin
released into the circulation would be of great benefit.
Due to the fact that IDDM is a disorder in which β-cells in the pancreatic islets of Langerhans
are selectively destroyed by an autoimmune attack, cell replacement strategies offer a very
attractive treatment option. Recent successes in the field of islet cell transplantation have led
to renewed optimism in this area. Clinical trials clearly demonstrated that islet transplantation
not only offers a viable option for patients with severe forms of IDDM, but can successfully
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treat the disease [2,3,4]. It is, however, apparent that islet transplantation is not currently a
viable option for the treatment of all potential recipients, due to the limited source of islet cells,
i.e. limited number of available donors. Another feature of islet transplantation, as currently
performed, is the requirement for life-long immunosuppression that limits the patients’
eligibility to individuals with the most severe cases of IDDM. These issues have driven the
investigation of alternative cell sources, which include xenografts from other species, embry‐
onic and adult stem cells, and gene therapy products. Such therapies will also likely require
immunological protection provided by means such as conventional immunosuppression,
administration of immunomodulatory cell subsets or a combination and manipulation of the
islets by shielding and/or encapsulation, which can protect transplanted cells from recognition
by the immune system and, in particular, from recurrence of autoimmunity.
An adult pancreas contains approximately one million (1 x 106) islet cells, which represent a
minor part of the organ, i.e. 2-3 % of the pancreatic tissue. Islets designated for transplantation
must be isolated from the whole pancreas using the method that combines enzymatic digestion
with mechanical disruption. Despite considerable improvements made in the islet isolation
process (the process itself, the reagents used during the procedure), that led to improved
quantity and quality of islet preparations, it still remains a largely inefficient process. Clinical
symptoms of Type 1 diabetes do not develop until 60-80% of the β-cell mass is lost to the
autoimmune attack [5]. This means that adequate glycemic control can be maintained with as
little as 20-40% of the normal β-cell mass. Intrahepatic islet transplantation is the accepted gold
standard at the present time. Ample scientific evidence suggests [4] that a significant number
of islets are lost during the immediate post-transplant period, mostly due to the inflammation
and thrombosis following initial islet-blood contact and activation of hepatic microenviron‐
ment. Thus, if the goal of islet transplantation is to replace 1 x 106 islets to achieve long-term
normoglycemia, several donors may be requires for each recipient. In fact, it has been previ‐
ously demonstrated [2,3] that insulin independence is achieved with ≥13,000 islet equivalents
(IEQ)/kg of recipient body weight, using more than one islet preparation per recipient, at the
same time or in succession. This means that a single islet transplant may require 3-4 donor
pancreata. At the present time, the only source of islet cells are pancreata obtained from a
deceased, heart-beating, brain-dead donor. This type of donor, especially of suitable age, is
rare, making current protocols for human islet transplantation an unlikely candidate for
widespread treatment for patients with IDDM. In the US alone, there are approximately 2
million people diagnosed with Type 1 diabetes. This demand is driving the current research
trends into alternative functionally competent, i.e. insulin secreting and sensing, β -cell sources
as potential replacement therapies for IDDM.
A number of different cell types have been proposed as a starting material to generate sufficient
cell mass for transplantation; these include insulin-secreting cell lines, non-β-cell sources
engineered through gene therapy, β-cells from non-human species, and β-cells generated from
adult (bone marrow, pancreas, liver and neural tissue) and embryonic stem cells [5]. Regardless
of the cell source, i.e. β- or non-β cells, many agree that the optimal treatment for Type 1
diabetes should ideally consist of an autologous cell source, which can synthesize, store and
release insulin in a highly regulated fashion to maintain glucose homeostasis. Too much or too
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little is potentially lethal, so the cells must be able to rapidly respond to changes in plasma
glucose in either direction.
This chapter will offer a detailed discussion of the latest developments in islet transplantation
and its future direction. In addition, attention will be paid to alternative approaches for
achieving insulin homeostasis and glycemic control through various novel cell replacement
therapies, as well as potential advantages and risks associated with each therapeutic option.
1.1. Allogeneic islet transplantation
Diabetes Mellitus (DM) poses a significant challenge in the United States and around the
world. It’s increasing in prevalence and, at the present time, affects almost 20 million peo‐
ple in the United States alone [1]. DM is considered to be the sixth leading cause of death
in the USA and is a major morbidity hazard [6,7] because of its associated complications
that may negatively impact a patient’s quality of life. Presently, the disease lowers aver‐
age  life  expectancy  by  about  15  years,  increases  cardiovascular  disease  (CVD)  risk  by
about two- to four-fold, and is the main cause of kidney failure, lower limb amputations,
and adult-onset blindness. DM is a costly disease: its estimated attributable costs in 2010
were approximately 135 billion dollars [6].
IDDM has an early childhood or young adulthood onset, although it can be diagnosed at any
age. It is characterized by profound deficiency in insulin secretion caused by the autoimmune
destruction of insulin-producing cells in the pancreas, the pancreatic β-cells. IDDM accounts
for approximately 5-10% of all disease cases. Factors that have been associated with the
development of Type 1 DM are both genetic and environmental [8-10]. In animal models such
as the NOD mouse and BB rat, and in human Type 1 diabetes, there is strong evidence of a
role of the class II gene, I-A in NOD mouse (equivalent to human DQ beta gene), most probably
in combination with lack of I-E expression (equivalent to human DR) [11]. Although it is
entirely possible that the genetic response can be triggered by environmental factors such as
infections or drastic change in diet, the clear definition of such factors has been elusive to date
[11]. Ultimately, though, it is the autoimmune component of Type 1 diabetes that is responsible
for the progressive and selective autoimmune destruction of insulin-producing β-cells in the
pancreas. Due to the fact that the disease is the result of the loss of a single cell type, i.e. β-cell,
it is considered to be amenable to treatment by cell replacement therapy.
The  discovery  of  insulin  in  1922  by  the  Canadian  physician  Frederic  Banting  brought
about  the  realization  that  it  was  the  pancreas  that  produced  the  “sugar-reducing  sub‐
stance” [1], i.e. insulin. Since then scientists have been interested in how this hormone is
synthesized and secreted, and the main therapeutic approach to IDDM has been focused
on insulin  replacement.  Until  recently,  the  only  available  treatment  for  Type 1  diabetes
was the administration of exogenous insulin. The Diabetes Control and Complications Tri‐
al (DCCT) [12] demonstrated that, in patients with Type 1 diabetes, intensive insulin re‐
placement therapy can control blood glucose levels to a certain extent [12]. Unfortunately,
even intensive care it is not able to mimic normal hormone release that regulates glucose
homeostasis [8] and results in the fine-tuned physiological balance [13]. Even in patients
with good glycemic control achieved through intensive insulin therapy blood glucose lev‐
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els can vary greatly outside the normal range [13]. In addition, tight control of blood glu‐
cose levels often results in frequent episodes of hypoglycemia. The DCCT trial [12] clearly
demonstrated that although intensive insulin therapy is able to delay the onset of diabe‐
tes-associated complications, it doesn’t result in complete prevention of their development
[12,13].  It  is  also not clear as to how early in the progression of the disease glucose ho‐
meostasis must be restored to affect a near-positive outcome.
Thus,  the need for  alternative or  additional  therapies  has been apparent  for  some time.
Endocrine replacement has been but one approach in the quest for tight glycemic control.
Achieved  either  through  transplant  of  a  whole  pancreas  [14]  or  allogeneic  islet  cells
[13-15], it  has been investigated for quite some time now. There is little doubt that pan‐
creas transplants, especially when performed simultaneously with a kidney, favorably im‐
pact metabolic control [14]. Eighty percent of the patients receiving simultaneous kidney-
pancreas  transplants  demonstrate  good  graft  function  and  insulin  independence  at  one
year following surgery, with 50% of the recipients maintaining euglycemia at 5 years [16].
Pancreas  transplantation results  in  independence from exogenous insulin,  normalization
of glucose levels (both fasting and post-prandial),  normal Hemoglobin A1c (HbA1c) lev‐
els, and freedom from hypoglycemia [16]. However, pancreas transplantation is still asso‐
ciated  with  significant  morbidity  and  mortality  rates  [16-18].  Thus,  most  patients  with
Type 1 diabetes are not candidates for pancreas transplantation.
In contrast, islet transplantation requires only a safe interventional radiology technique to
implant the graft, and doesn’t require general anesthesia, does not call for post-transplant
management of pancreatic secretions, and is not associated with post-transplant morbidity
and mortality. In addition, in patients with Type 1 diabetes, pancreatic exocrine tissue, which
represents the vast majority of the organ, is not affected. These are all factors that contribute
favorably toward a wider application of islet cell transplantation.
Of the 159 islet cell allografts reported to the International Pancreas Transplant Registry [18]
in 1983, none resulted in insulin independence that could be clearly linked to the implanted
graft. These unsatisfactory results could be attributed to the suboptimal islet isolation methods
and variable immunosuppressive regiments utilized at the time. It is now apparent that islet
isolation methods used at that time - originally developed for the isolation of rat islets by
Moskalewski19 and further improved upon by Lacy [20] - were not entirely adequate for the
isolation of human islet cells. The use of unpurified islet preparations was not particularly safe,
resulting in reported cases of portal hypertension and even death [21].
Introduction of collagenase through the pancreatic duct during the distension of the organ,
and purification of the islet cells from the exocrine tissue using discontinuous Ficoll gradients
[22, 23] resulted in the optimization of the islet isolation method, i.e. improved isolation yield
and islet purity of up to 90% [9]. These continued improvements in the islet isolation meth‐
odology provided a new impetus to continued attempts at islet transplantation during the
1980’s. Although none of the islet allografts resulted in insulin independence, clinical trials
conducted during this period proved islet cell transplantation to be safe, and for the first time
demonstrated a sustained C peptide production [24].
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In the 1990’s, the International Islet Registry [25] reported that 10% of the patients receiving
allogeneic islet grafts could maintain insulin independence at ≥1 year following transplant.
Although the majority of transplant recipients continued to require some exogenous insulin,
their daily insulin intake was reduced, HbA1c decreased, and they reported fewer episodes of
hypoglycemia unawareness. At this point, transplantation of allogeneic islet cells became a
reality. However, questions related to partial graft function and eventual graft failure due to
recurrence of auto-immunity or rejection - both difficult to predict - remained. Animal studies
of glucose metabolism in rat [26], dog [27-29] and cynomolgus monkey [30,31] models
demonstrated that long-term normoglycemia could be achieved provided that a sufficient islet
mass was transplanted. These studies also showed that, in dog and simian models, the site of
implantation did not play a significant role in graft failure. These findings demonstrated that
islet transplantation could be successful, and represented a sustainable cell-based treatment
for patients with Type 1 diabetes.
Of significant, positive impact was the introduction of the Ricordi automated method for islet
isolation [32] which allowed for continuous release of large numbers of islet cells during the
digestion phase, protecting them from any further enzymatic action, thereby preventing over-
digestion of the islet tissue, and significantly reducing islet cell loss as a result of the isolation
process. The digestion process was allowed to proceed until only a fibrous network of ducts
and vessels of the pancreas remained. In contrast with previous methods utilized to isolate
human islets, the Ricordi method allowed for the digestion of the whole pancreas and a
significant improvement in the quantity and quality of the isolated cells [32]. Introduction of
more efficient enzyme blends [33,34], development of more effective organ preservation
methods [35-37], effective use of semi-automated large-scale purification techniques [38-41],
and the introduction of additional reagents during various phases of islet cell processing, all
contributed to the improved islet recovery and the utilization of islet preparations for trans‐
plantation. Islet preparations can be transplanted fresh, i.e. immediately following isolation,
or following culture [2,3], which is of substantial benefit. This window offers sufficient time
for both the detailed characterization and quality assessment of the islet preparation, and
shipment of the cells to satellite transplant centers, when necessary.
Islet preparations of various degree of purity are normally implanted into the recipient’s liver
portal vein by transhepatic cannulation using minimally invasive interventional radiological
techniques [42-47]. This approach has been demonstrated to be safe, is associated with low
morbidity and is well tolerated by the transplant recipients. In fact, when additional islet mass
is required to improve recipient’s metabolic control, additional preparations of islet cells are
delivered using the same route of administration.
New immunosuppressive protocols designed for the recipients of solitary islet allografts, i.e.
islet transplant alone (ITA), and the publication of the results of the Edmonton Protocol in the
year 2000 [2,3] lead to further improvement in the clinical outcomes reported by a number of
centers [42,48-50]. These new protocols moved away from the use of glucocorticoids and
calcineurin inhibitors (CNI, cyclosporin A (CyA)) that have diabetogenic effects, and potential
islet toxicity [2,3,42,48-50]; and utilized alternative strategies as immunosuppressive therapy.
On-going clinical studies clearly demonstrated that allogeneic islet transplantation has the
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potential to become a viable therapy for patients with severe forms of Type 1 diabetes.
However significant challenges need to be overcome before islet transplantation can be
considered as the treatment of choice.
Some of the critical questions that remain to be addressed include: (i) definition of an adequate
supply of donor organs which can meet the existing need; (ii) isolation of a sufficient number
of high quality islet cells from the exocrine tissue, which comprises 98-99% of the pancreas;
(iii) improvements in the immunosuppressive strategies that are currently used, by either the
development of less toxic drugs or the induction of tolerance; (iv) preventing the recurrence
of autoimmunity, demonstrated to have successful outcomes in murine models [5]; (v)
identifying the early occurrence of immune rejection, which is quite challenging to monitor
given the very small volume of the transplanted tissue and our limited ability to characterize
the process.
1.2. Islet cells from xenogeneic sources
At the present time xenogeneic islet cells isolated from pig pancreata offer the most promising
alternative to human islets as a treatment for Type 1 diabetes. This is based on a number of
observations: (i) there is a large number of facilities in the US with capabilities for high-
throughput breeding, rearing and slaughter of pigs; (ii) pig insulin differs from human insulin
by just one amino acid and has been successfully utilized as a source of exogenous insulin for
many years before the advent of recombinant insulin; (iii) large numbers of islet cells can be
isolated from a single pig pancreas using techniques similar to those developed for human
islet isolation; (iv) pig donors can be genetically manipulated to increase insulin production,
and to protect the islet cells from immune and cytokine assault [5,51].
Several limitations have restricted the use of pig islets in human recipients. The first one
is  the  hyperimmune  response,  possibly  mediated  by  the  galactoseα  -1,3-galactose  (Gal)
epitope. Elimination of this epitope was shown to prevent hyperacute rejection of pig-to-
nonhuman primate solid organ xenografts. Immune protection of xenografts utilizing en‐
capsulation techniques resulted in progressive loss of graft viability and insulin secretion
over prolonged period of  time,  during which transplanted islets  were expected to func‐
tion [52]. The second one is the possibility of transmission of porcine endogenous retrovi‐
ruses (PERV), several copies of which are present in the genome of all  pigs and able to
infect human cell in vitro, with unknown consequences [53]. The possibility of novel viral
infections in recipients of porcine islet grafts raised serious safety and ethical concerns, as
C-type retroviruses  related to  PERV have been demonstrated to  associate  with  hemato‐
poietic cell malignancies in the natural hosts [53].
The interest in porcine islets peaked when it was demonstrated that T-cell immunomodulatory
therapies which target indirect co-stimulatory pathway, i.e. CD28-CD154, supported pro‐
longed engraftment of unmodified pig islet cells in non-human primates [54, 55] Furthermore,
published data drew attention to the fact that, in contrast to human islets that produce copious
amounts of islet amyloid polypeptide (IAPP) capable of inducing β -cell apoptosis, pig neonatal
and adult islets do not form amyloid deposits. This could be due to the fact that pig IAPP is
considerably less amyloidogenic [56]. Recently published data, however, have suggested that
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the PERV scare may have been overestimated: long-term immunosuppressive regimens and
exposure to porcine islet grafts did not result in any detectable PERV transmission. These data
clearly showed (a) no expression of PERV in porcine islets in either in vivo or in vitro studies,
and (b) no integration of PERV sequences into recipient cell or organs [55, 57-58]. Additionally,
Koulmanda et al successfully demonstrated that, following anti-CD4 treatment, pig islet grafts
became resistant to autoimmune destruction in non-obese diabetes (NOD) recipients, sug‐
gesting that CD4-mediated autoimmunity, rather than hyper-acute immunological response,
might be the cause of the destruction of xenogeneic islet grafts [59].
It is also difficult to overlook the fact that large numbers of porcine islets can be isolated with
considerable ease, using protocols similar to those developed for the bulk isolation of human
islet cells [32,60]. Since the introduction of highly efficient semi-automated methods for bulk
islet isolation of pig pancreatic islets by Ricordi et al [32], the quantity and quality of islet
preparations from a pig donor has been consistently higher. Pig donors are healthy and avoid
cell senescence due to various co-morbidities, brain death, and cold and warm ischemia injury,
as these factors can be controlled and, under normal circumstances, kept to a minimum [60,61].
Using standard purification methods [61] a purity of 70-90% of islet can be achieved. Islet cells
isolated from adult pigs are functionally competent, and graft function can be recorded shortly
following transplantation [61]. In addition, adult pig islets have appropriate glucose-sensing
and insulin release mechanisms, as demonstrated by prolonged diabetes reversal when
porcine islets were transplanted into nonhuman primates [534,55]. However, the fragile nature
of adult porcine islets leads to significant loss as a result of ischemia and inflammation, during
cell culture and early engraftment process. It also makes it challenging to maintain them in
culture, and may result in the loss of a significant proportion of cells following isolation.
Although a reduction in islet mass and cell viability has been reported when adult porcine
islets were maintained in culture, short-term culture is desirable to reduce cell immunogenicity
or combine preparations from several donors, prior to transplant [61].
In comparison to adult pig islets, fetal islets have been isolated with even greater ease. Once
isolated these require several weeks of culture to facilitate re-aggregation of the endocrine
tissue and elimination of exocrine tissue, and to mature to glucose-sensing and insulin
production [60]. Additionally, immature cells are much more resistant to the ischemia and
inflammation-related injury. Fetal islet isolation is very simple and highly reproducible, and
can be accomplished using an exogenous solution of digestive enzymes with minimal loss of
immature islet cells [61]. This is due to the fact that fetal islet tissue is not prone to ischemic
damage, most probably because of its inherent relative lack of exocrine tissue, capable of
inducing damage as a result of the release of proteolytic enzymes from damaged exocrine cells
[62,63]. At the same time, there is a relative abundance of endocrine tissue which makes the
isolation of fetal islets an easier and more efficient process. Additionally, the copiousness of
immature precursor cells in the ductal tissue and their possible presence in the islet-like cell
clusters (ICCs) that form during culture, contributes to high capacity of ICC tissue for post-
transplant proliferation, a key feature lost in adult pig islets [63]. Thus, small numbers of ICCs
can eventually produce large-size grafts, provided that rejection, recurrence of autoimmunity
and hyperglycemia can be overcome and controlled [63]. Considering the small size of the fetal
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pancreas, the capability of a small number of ICCs to mature into a functionally competent
graft speaks to the use of this tissue. As mentioned above, a major drawback with using
functionally immature cells is their delayed function. ICCs require several weeks, and even
months, of development before normal glucose levels in the recipient can be achieved, during
which time a poor response to physiological glucose has been observed [64]. This on-going
hyperglycemic state during the period of functional maturation can lead to possible damage
of the transplanted fetal tissue. Thus, while transplanting immature ICCs in diabetic recipients
who are early in the course of their disease might not represent a problem, it is potentially a
serious drawback for patients with brittle diabetes and declining kidney function [51,62]. A
second disadvantage to using ICCs is the high expression of α-1,3-Gal epitope on the surface
of fetal islets, making these cells more susceptible to rejection than adult pig islets, which in
contrast express little Gal [62].
Neonatal pancreatic cell clusters (NPCCs) obtained from 1-5 day-old piglets can be also easily
procured and successfully isolated in a relatively quick and efficient manner [61,65], using
culture media supplemented with collagenase. Due to their availability and inherent capacity
to differentiate in vitro and in vivo, NPCCs represent an attractive source of xenogeneic tissue
for clinical transplantation. Although freshly isolated cell clusters contain only 7% endocrine
cells, 11% epithelial cells, and ~74% exocrine tissue, this content undergoes dramatic transfor‐
mation following a 9-day culture [51,61]. Published data indicates that during in vitro culture
the acinar tissue undergoes apoptosis resulting in the enrichment of the endocrine component
to 35% [61] of the total cellular content, with 25% of the cells capable of insulin production.
The rest of the tissue is characterized as non-granulated epithelial cells [61]. In vitro culture
results in the formation of NPCCs [61,65], as well as the proliferation of β-cell as assessed by
studies using bromodeoxyuridine (BrdU) [65]. NPCCs have been demonstrated to be more
responsive to glucose challenge compared to the fetal ICCs, but not as fully functional as adult
islets [61]. Although NPCCs were showed not to correct diabetes immediately following
transplantation, the insulin content of the grafts was reported to increase by ~20 fold [61],
confirming either NPCCs’ capacity for β-cell proliferation, or differentiation of epithelial
precursor cells into β-cells, or both. During the period of hyperglycemia, none of the trans‐
planted immunodeficient mice were lost, suggesting that even in the immediate post-trans‐
plant period NPCCs are capable of producing small, but sufficient, amount of insulin to keep
the recipients alive, stopping short of achieving normoglycemia [61]. This speaks to the fact
that compared to the adult porcine islets, NPCCs have an extensive in vivo and in vitro
proliferative capacity [61,65], as well as the ability to acquire endocrine function in a time-
dependent manner. In addition, data showing that NPCC can be successfully and reproducibly
transfected with a non-immunogenic, non-pathogenic recombinant AAV demonstrated a
possible strategy for gene delivery to improve transplantation outcome [65].
On the other hand, NPCCs require long periods of in vivo maturation before developing
functional competence [65], which represents a potential draw-back with respect to the clinical
utilization of this xenogeneic islet cell source.
Small and large animal models to study the potential clinical use of porcine islet transplanta‐
tion to treat Type 1 diabetes have been developed and success has been reported [54,55,59,61,
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62]. Reversal of diabetes with prolonged restoration of insulin independence has been achieved
in several porcine-to-nonhuman primate xenogeneic transplant models [54,55] in recipients
that developed diabetes as a result of chemical treatment, surgical intervention, i.e. pancreo‐
tectomy, or spontaneously. Long-term insulin independence has also been achieved when
neonatal and fetal pig pancreatic precursors were implanted intraportaly, subcutaneously, and
into the peritoneal cavity [66,67]. The choice of the anatomical implantation site for not only
porcine, but human islets is crucial. At the present time, the accepted clinical practice is to
deliver islets to the liver, through the portal vein. However, it has been demonstrated that
using this route of administration, low oxygen tension, and an active innate immune response
that results in complement activation and immediate blood-mediated inflammatory response
(IBMIR) contribute to significant islet mass loss in the immediate post-transplant period
[68,69]. Different challenges arise when the graft is placed under the kidney capsule, i.e. islets
in this case may be damaged by stress as a result of ischemic injury. However, implantation
of encapsulated porcine islets under the kidney capsule of non-diabetic Cynomolgus Maca‐
ques resulted in low levels of porcine C-peptide, with islet grafts surviving for up to 6 months
[70]. Reports of other implantation sites, such as subcutaneous and peritoneal space, have been
published, but both have been reported as relatively immunoreactive [51], unless the islets
were protected by an immune barrier in the form of a capsule.
Although most of the data regarding the possible use of porcine islets as an alternative
treatment modality for Type 1 diabetes became available as a consequence to the extensive
effort undertaken in a number of small and large animal models, a number of reports of
controversial clinical trials have been published in the last several years. An Australian
biotechnology company, Living Cell Technologies Ltd., reported a clinical trial in Moscow
where 10,000 encapsulated porcine islet equivalents (IEQ)/kg recipient body weight isolated
from adult virus-free pigs (DiabeCell®) were implanted into several adult recipients with
brittle form of Type 1 diabetes, leading to reduced insulin requirements and detectable porcine
C-peptide 11 months following transplant [71]. Follow-up dose-finding clinical trial conducted
in New Zealand, however, produced less optimistic results. Although a statistically significant
reduction in hypoglycemic unawareness was demonstrated, insulin requirements and C-
peptide were reported to be largely unchanged. Additional dose-finding trials using Diabe‐
Cell® are currently in progress. Earlier clinical trials conducted in Mexico utilized neonatal
islets co-cultured with Sertoli cells in a collagen-coated device which was implanted subcuta‐
neously into 12 adolescent Type 1 diabetic patients [72]. Although pioneering in nature, this
work drew a certain amount of criticism with regard to the ethical implications of conducting
clinical trials in countries without strict regulatory oversight, the dearth of relevant pre-clinical
data to warrant Phase I clinical trials to assess the safety of the investigational therapy, i.e.
porcine islet transplants, as well as the efficacy of the treatment [73].
It’s hard to dispute potential clinical and commercial implications of porcine xenotransplan‐
tation as a potential therapy for patients with severe forms of Type 1 diabetes. Although not
a new idea, recent developments in this field are likely to drive larger, more tightly controlled
pre-clinical and clinical studies to explore its enormous potential as a substitute for human
islets. However, if xenotransplantation is going to be the way to solve inherent supply
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problems with allogeneic organs, a much better understanding of the immunological processes
involved in the destruction of xenogeneic tissue is necessary.
1.3. Stem cell as β-cell replacement therapy
The most promising cell source for β-cell progenitors is embryonic stem cells (ESCs) derived
from the inner cell mass of blastocysts during the early stages of embryogenesis. ECSs offer
several notable advantages. First, ESCs differ from adult stem cells in that under the right
growth and differentiation conditions they have the potential to differentiate into any cell type
in vitro and in vivo, a potential termed pluripotency. Given the capacity for pluripotency, there
is an interest to explore guided in vitro differentiation into a desired cell type for the purpose
of cell replacement therapy, in this case for the treatment of Type 1 diabetes. Second, ESCs’
potential to self-renew while maintaining their stem cell properties is of immeasurable
advantage, as it allows for unlimited cell expansion, while the cell differentiation capacity is
preserved. Given the need for large number of cells for therapeutic applications, this favors
ESCs over the cells at more advanced stages of maturation which, in general, are reported to
have a much more limited proliferative capacity [74]. Here, of course, certain precautions are
necessary. Directed cell differentiation and proliferation also results in the differentiation of
associated cell types, which are not necessarily desired and need to be inhibited. This repre‐
sents a challenge. It’s been previously postulated that to successfully differentiate a cell type
such as insulin-producing β-cells, an ideal protocol would involve culture steps that mimic a
differentiation process taking place during normal embryonic development. That involves
certain signaling pathways and transcription factors necessary to guide the development of
undifferentiated progenitor cells into fully mature, metabolically functional insulin-producing
β-cells [74-76].
First attempts to generate insulin producing islet-like cells (IPCs) were centered on the
selection of cells positive for nestin, an intermediate filament protein which serves as a neural
stem cell/progenitor marker [77-79]. The reason behind the focus on nestin-positive cells is that
in some species neural cells, namely brain neurons in Drosophila, are the source of circulating
insulin. In addition, insulin gene transcription is found in the vertebrate brain, although it’s
not clear if vertebrate neurons produce or secrete the actual protein [74,78]. Recent reports,
however, have demonstrated that selection of nestin-positive cells from ESCs leads to gener‐
ation of neural cell types [80-82], although differentiation into insulin-producing cells was also
achieved. This is consistent with the fact that nestin is a marker of neural and pancreatic
exocrine progenitors, but does not indicate endocrine progenitor cells. Attempts to differen‐
tiate brain-derived neural ESCs into insulin-producing cells resulted in the formation of
glucose-sensing insulin producing cell clusters following the exposure to multiple signals that
regulate in vivo islet pancreatic development [83]. Following transplantation into immuno‐
compromised mice islet-like clusters were demonstrated to release insulin and C-peptide.
However, the C-peptide content of these islet progenitor clusters was estimated to be 0.3% of
the normal level found in isolated human pancreatic β-cells [83], suggesting that the resulting
islet-like cell clusters were not bona-fide β -cells. In addition, temporal sequence of expression
of gene products active during the development of pancreatic islet cells, such as glucokinase,
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Glut-2 and Pdx1, did not exactly resemble that observed in the embryonic pancreas; nor was
the transcription of other genes normally expressed in β-cells, such as Nkx2-2 and Nkx6-1,
detected in the later stage islet-like clusters. Some of these insulin-producing cell clusters [77],
while staining positive for insulin, were - in all likelihood - the result of insulin uptake from
the culture medium, rather than activation of robust insulin transcription, as demonstrated by
other studies [84]. These data pointed to the fact that evidence demonstrating the equivalence
of these islet-like cells clusters to mature β-cells was lacking; and that a better understanding
of the signaling pathways and transcriptional factors regulating the development of pancreatic
β-cell identity during embryogenesis was necessary.
In 2005, D’Amour clearly demonstrated that cells closely resembling fully mature native β-
cells could be generated by replicating the culture conditions that closely mimicked embryonic
development [85,86]. Utilizing a step-wise approach, ESCs were first directed into definitive
endoderm stage, a pre-requisite for all pancreatic cell types, followed by a pancreatic endo‐
derm, and subsequently into β-cells with an insulin content similar to that observed in native
islets [86]. However, similar to fetal β-cells, the resulting cells were able to release C-peptide
in response to multiple secretory stimuli, but only minimally to glucose. These studies were
followed by others [87-89] in which these cells were implanted into immunocompromised mice
half way through the differentiation process. When the cells were allowed to mature in vivo,
the efficiency of the differentiation process was improved, glucose-responsive insulin secretion
observed, and chemically induced diabetes reversed [89]. Progress in this area has been rapid
and recently, California-based ViaCyte (previously Novocell) has reported positive pre-
clinical results with Pro-Islet™, a material based on the technology discussed above, in
conjunction with a retrievable encapsulation device. On-going efforts to translate this strategy
into pre-clinical and clinical applications were supported by a recent $20 million award from
the California Institute of Regenerative Medicine. This works favorably towards ESC-based
clinical approaches becoming available in the very near future.
Upon demonstration that the mature state of somatic stem cells can be redirected toward the
a progenitor state similar to that of ESCs [90-92], the field of stem cell-based strategies has been
further expanded and now includes an attractive alternative to ESCs, i.e. induced pluripotent
stem cells (iPSCs). Potentially, iPCSs offer a practical solution to the ethical dilemma posed by
the destruction of human embryos necessary for the production of ESCs-based cell therapies.
These cells, they are virtually undistinguishable from ESCs in terms of their molecular and
biological characteristics. They offer a possibility of generating autologous patient-specific cell
therapies directed to treat a variety of medical conditions, including diabetes. This means that
depending on the specific illness, desired cells can be differentiated from the patient’s own
cells. This is certainly attractive as the cells designated for re-transplantation would have the
same genetic makeup as those of the patient, and would alleviate the challenges posed by the
activation of the recipient‘s immune system that would occur when allogeneic cells are
transplanted.
In 2006, Takahashi et al [90] demonstrated that pluripotent stem (iPS) cells could be generated
from mouse fibroblasts by the retrovirus-mediated transfection of four transcription factors,
namely Oct3/4, Sox2, c-Myc, and Klf4. Since then, following the main steps of the original β-
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cell differentiation protocol and retroviral expression of the same four transcription factors, it
was reported that differentiation into insulin-producing islet-like clusters was possible. Islet-
like clusters were obtained from iPSCs using a serum-free, feeder-free protocol [93]. Following
initial reports, a number of modifications to the original protocol have been introduced. These
included substituting the originally-described transcription factors with oncogenic potential
with stable recombinant proteins [94], episomal constructs [95], DNA minicircles [96],
modified mRNAs [97], and small molecule compounds with re-programming properties [98].
Despite these efforts, generation of patient-specific cell lines form iPSCs remains inefficient
and expensive, hindering progress in this area. Additionally, there seem to be an inconsistency
in the methods utilized for the successful differentiation of insulin-producing islet-like cells,
leaving the field open for a much wanted universal protocol utilized to generate a wide variety
of patient-specific cell lines, much like that developed by ViaCyte for the Pro-Islet™ technol‐
ogy. Then, of course, the risks inherent to the use of iPSC-and ESC-based approaches must be
carefully considered, as these seem to be almost identical.
First, there are the reports of teratoma formation when undifferentiated (cultured in vitro for
~12 days) ESCs are utilized in pre-clinical models [89]. Interestingly, when cells cultured under
similar conditions for extended period of time were utilized [87], no teratoma formation was
observed in recipient animals suggesting that more extensively differentiated ESCs lose their
ability for neoplastic transformation. Hence, teratoma formation can probably be controlled
through elimination of less differentiated cells via advanced purification techniques, as well
as more efficient machinery for cell differentiation.
Another critical aspect that deserves serious consideration is related to the full cell complement
present at the final ESC differentiation stages. Transplantation of pancreatic progenitor cells
results in the development of not only the endocrine cell types, the full complement of which
are probably required for fully functional islet structures, but also the exocrine pancreas, i.e.
acinar and ductal cells, albeit at much lower frequency [89]. The presence of these cells that
have the ability to produce and release various enzymatically active proteins is worrisome. In
addition, under conditions of stress caused by inflammation and injury, acinar cells can
develop into cells with progenitor-like activity, able to result in neoplastic lesions as a result
of oncogenic mutations. While the possibility of such events is small, detailed investigation
into these issues needs to continue to assure that the function of ESC-derived endocrine cells
are not compromised by the cancer-related risks associated with exocrine cell populations.
Another issue that needs to be explored is the immune response of the host following trans‐
plantation of an allogeneic ESC-derived cellular graft. In the last decade or so sophisticated
immunosuppressive regiments have been developed to protect allogeneic islet grafts obtained
from deceased donors [46-50] long term, following transplantation. In case of ESC-related
therapies, not only the graft must be protected from the immune insult by the recipient’s
immune system, but the cells with tumorigenic capacity need to be isolated and sequestered.
This can be, most probably, achieved with the use of sophisticated immunoisolation / encap‐
sulation devices that have become available in the last few years [4].
Finally, what needs to be ascertained is the fact that stem-cell derived β-cells have the same
ability to synthesize, store and release insulin in a highly regulated fashion similar to that of
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native pancreatic islets. Extensive efforts should be undertaken to understand whether the
same regulatory mechanisms are in place in stem cell-derived insulin producing cells to control
prolonged and uncontrolled insulin release which would result in sever hypoglycemia. Only
when it is clearly and unequivocally ascertained that stem cell-derived insulin producing cells
are true equivalents of endogenous pancreatic β-cells, can clinical application of such therapies
become a reality.
1.4. Immunotherapy for the prevention and treatment of Type 1 diabetes
As Type 1 diabetes is an autoimmune disease characterized by the selective and progressive
destruction of insulin-producing β-cells via the cumulative attack by autoantigen-specific
CD4+ and CD8+ T-cells, autoantibodies, and functionally defective bone marrow derived
antigen-specific cells, development of various immunotherapeutic options has been the major
focus for prevention and treatment of IDDM. Multiple studies in the NOD mouse model
demonstrate that islets are attacked in step-wise manner, with benign insulitis being the
starting point of this assault. With time and not fully defined qualitative changes, overt
diabetes characterized by the efficient destruction of β-cells ensues. It is generally acknowl‐
edged that diabetes in animal models and men is strongly associated with the changes in more
than 20 genetic loci - with genes encoding MHC class II molecules playing the major role, most
probably influenced by a number of environmental factors, although it’s been quite challeng‐
ing to identify either in detail [11].
Animal studies indicate that a number of pathogenic events contribute to the progressive loss
of T-cell tolerance to β-cell proteins, and, therefore, expansion of β-cell specific pathogenic
CD4+ and CD8+ T-cells. These events seem to take place during the early stages of the pre-
clinical IDDM. These include defective negative selection in the thymus, inefficient peripheral
tolerance characterized by low frequencies of IL-4, IL-10 and TGF-β secreting CD4+ T helper
2 (Th2) cells, as well as diminished numbers of “natural” immunoregulatory FoxP3 expressing
CD4+CD25+ Regulatory T (Treg) cells and invariant natural killer T (iNKT) cells. These events,
coupled with reduced frequency / function of immunoregulatory effector cells within the islets,
reduced sensitivity of T cells to immunoregulation, and increased levels of pro-inflammatory
cytokines produced by macrophages and dendritic cells (DCs), result in the severe loss in the
balance between pathogenic effector and immunoregulatory T cells, especially during the later
stages of the disease [99-101]. Effective prevention / treatment strategies for Type 1 diabetes
must focus on the restoration of this balance..
The progression course of diabetes offers obvious time points for interventional immunother‐
apeutic strategies. The first opportunity is presented during the pre-clinical stages of diabetes,
when the goal is to suppress the on-going β-cell autoimmune process and prevent the
development of overt diabetes. Undiagnosed at risk individuals - family members of patients
with the previously diagnosed diabetes - can be monitored by screening for autoantibodies
specific for several autoantigens found in the serum. These include insulin, glutamic acid
decarboxylase 65 (GAD65), and insulinoma–associated tyrosine phosphate (IA-2) [102]. The
second time point for intervention is at clinical onset, in an attempt to preserve 10-15% of the
β-cell mass that is usually still present at the time of diagnosis.
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There is a definite therapeutic potential through the rescue of the residual β-cells, and there
are reports that halting autoimmunity at this stage can potentially lead to β-cell regeneration
and/or replication and, in ideal circumstances, remission of diabetes [103,104].
Further down the line, when all  β-cells are lost,  the likelihood of remission through im‐
munoregulation becomes slim,  but  recent  observation in  clinical  trials  performed in  pa‐
tients  with  undetectable  C-peptide  suggest  that  restoration  of  β-cell  function  is  not
impossible in these circumstances. A recent clinical trial conducted in China demonstrated
that following treatment with autologous lymphocytes and allogeneic cord blood-derived
stem cells, patients with and without residual β-cell function demonstrated improved C-
peptide levels, reduced median Glycated hemoglobin A1C (HbA1C) values, and decreased
daily insulin requirements [105].
The development of specific immunotherapeutic strategies that effectively target pathogenic
effector cell populations, promote β-cell tolerance, while maintaining a “normal” immune
function, i.e. balance between pathogenic effector and immunoregulatory T-cells, is the
ultimate goal. This means that different immunotherapeutic strategies, alone or in combina‐
tion, must be considered to effectively suppress β-cell autoimmunity at different stages of the
disease progression.
There is sufficient information that deals with various immunotherapeutic strategies to
prevent / treat Type 1 diabetes, for which both clinical and experimental findings are available.
Two major approaches have received most attention, although others have been discussed,
namely, antigen- and antibody-based immunotherapies.
1.4.1. Antigen-based immunotherapy
Antigen-based immunotherapy has to do with selectively targeting disease-specific T cells to
maintain the normal function of the immune system. β-cell antigen-specific vaccination has
proved to be an effective strategy for the induction of the immunoregulatory T cells and
suppression of autoimmune pre-clinical diabetes in rodent models and NOD mice. Vaccination
of 12-week old NOD mice with GAD65 protein resulted in the inhibition of the progression of
insulitis and long-term protection mediated by the GAD65-specific CD4+ T cells [106].
Successful application of antigen-based immunotherapies in the clinical setting has yet to be
reported, although some evidence does exist of the successful application of this methodology.
The Diabetes Prevention Trial-1 (DPT-1), during which participating pre-diabetic subjects
received insulin either orally or parentally demonstrated no significant effect on the develop‐
ment of diabetes or β-cell autoimmunity [107]. Although the reason for why the treatment
failed to prevent diabetes in the majority of subjects was never clearly identified, it was thought
that insufficient dose of insulin administered to trial participants was the main culprit. One
interesting observation had to do with the fact that some effect was observed in subjects
receiving oral insulin that presented with high titers of insulin autoantibodies. It is, therefore,
entirely possible that success or failure, as well as efficacy, of a given antigen-based immuno‐
therapy is related to the severity of the existing autoimmunity.
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It’s been demonstrated that treatment with antigen-based therapy can have a dual effect on au‐
toreactive T-cells: induction of T-cell deletion and the induction of immunoregulatory T- cell
population [108,109]. The number of immunoregulatory β-cell specific T-cells induced as result
of treatment is critical. As diabetes progresses and the pro-inflammatory milieu is established, a
relatively high number of immunoregulatory T-cells would be required to effectively suppress
β-cell autoimmunity and to restore the balance between pathogenic effector and immunoregu‐
latory T-cell subsets. The number of inducible immunoregulatory effector cells is, at least in
part, dependent on the size of the pool of naive precursors for a given β-cell autoantigen
[101,106]. As the pool of β-cell specific T-cell precursors actively involved in the autoimmune
process is limited, minimizing the pool of immunoregulatory T-cells that can be induced, it is of
critical importance to choose the autoantigen utilized for treatment at late stages of the disease
wisely. While in experimental models it’s been demonstrated that administration of a combina‐
tion of β-cell autoantigens suppresses β-cell autoimmunity during the late stages of the disease,
the same has not been clearly defined in patients [101]. Although some progress has been made
towards the development of methods that can be used to detect β-cell specific T-cells, more de‐
velopment is necessary before this approach can become a standard immunotherapeutic ap‐
proach. In addition, as demonstrated by the DPT-1 [107], the efficacy of a given treatment, i.e. β-
cell autoantigen, may vary significantly between individuals, probably based on the extent of
autoimmunity, i.e. β-cell specific T-cell precursors. This means that, similarly to the NOD mod‐
el, immunization with the cocktail of various β-cell specific peptides would be necessary to ach‐
ieve a measurable degree of success in abating the progress of the autoimmune process taking
place during the advanced stages of Type 1 Diabetes.
The number of immunoregulatory β-cell specific T-cells induced as result of treatment also
depends on the efficiency of the process involved in the induction of immunoregulatory T-cell
population. What complicates matters is the fact that this induction must take place in vivo,
under the same conditions that favor the expansion of autoreactive β-cell specific T-cell subsets.
Hence, strategies that preferentially promote the expansion of immunoregulatory T-cell
populations are necessary. Properties of mucosal tissues [110,111], co-administration of
various types of adjuvants and cytokines, as well as manipulation of the way the autoantigen
is presented have been investigated in both experimental and clinical settings [107], with some
degree of reported success. In addition, variety of inducible immunoregulatory T-cell popu‐
lations has been reported to be of importance as induction of different types of immunoregu‐
latory cells, each with a distinct mode of action, would be expected to increase the overall
efficacy of a given immunotherapy [107].
1.4.2. Antibody-based immunotherapy
Various monoclonal antibodies have been utilized to target a wide range of immune compo‐
nents actively involved in the progressive autoimmune process. Most of these focus on directly
or indirectly targeting the T-cell compartment [101], but also include soluble mediators such
as cytokines and chemokines, and antigen presenting cells (APC). Several recent reports
suggest that B-cells may also represent a useful target to alter the progression of β-cell
autoimmune process.
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There is an abundance of literature that discusses the efficacy of monoclonal antibodies
targeting T-cells, in a number of experimental models. Following the administration of a short
course of depleting CD4 antibody or anti-lymphocyte serum in NOD mice, suppression of β-
cell autoimmunity and, in some cases, remission of the recent onset of diabetes is achieved
[112,113]. There is, however, a drawback to this approach. Depleting antibody immunotherapy
resulted in the indiscriminate depletion of not only the pathogenic, but also non-autoimmune
T-cell populations, and induced long-term state of immunosuppression. In addition, after the
depleting antibody was cleared from the system the number of T-cells that reappeared was
significantly reduced, compared to normal levels. At this same time, the use of non-depleting
anti-CD4 and CD8 antibodies resulted in tolerance induction in the antigen-specific manner,
with the T-cell numbers intact [114], induction of apoptosis in activated T-cells, and activation
of the CD4+CD25+FoxP3+ cell population demonstrated to have a suppressive effect on the
differentiation of pathogenic effector T-cells [114].
Studies investigating the efficacy of anti-CD3 monoclonal therapy for the treatment of Type 1
diabetes have been generating a lot of interest ever since they’ve been first reported [104],
Chatenoud demonstrated that a short course treatment of NOD mice with low dose anti-CD3
antibody resulted in long-term remission of recent onset diabetes and β-cell specific tolerance
[104]. The mode of action of this therapy proved to be multi-faceted. A critical observation was
of the anti-CD3 antibody preferentially affecting activated rather than naïve T-cells by down-
regulating the T-cell receptor and reducing TCR signaling, enhancing apoptosis, and altering
T-cell trafficking [115]. This treatment was also demonstrated to promote the expansion of the
immunoregulatory T-cells with CD4+CD25+ phenotype. Utilization of a non-mitogenic anti-
CD3 antibody in a clinical setting, during the first 6 weeks following diagnosis, resulted in the
preservation of C-peptide response over a 2-year period in certain patients relative to untreated
controls. The fact that residual β-cell function was reported in some patients at the time of
treatment speaks to the importance of therapeutic administration at “earlier” stages in the
disease progression [116]. Although efficacy with this treatment was observed, the protection
offered by the anti-CD3 antibody treatment was nevertheless transient. This suggests that this
type of therapy needs to be refined either in terms of schedule or route of the administration,
or the therapeutic dose, before it can be applied to a larger patient population.
Studies with monoclonal-based therapies targeting co-stimulatory pathway of immune
activation such as CD40-CD40L, and APCs such as DC’s and B-cells have also been reported.
Blocking the CD40-CD40L pathway proved highly effective in abrogating T-cell responses in
autoimmune and transplantation models [117]. However, before this approach could be
investigated further the anti-CD40L antibody was withdrawn from use in various clinical trials
due to serious adverse events that came into view as a result of treatment.
Targeting B-cells, whose primary role in Type 1 diabetes is that of APCs to T-cells, was never
high on the list of targets for potential immunotherapy. The reason behind this is simple: islet-
specific autoantibodies have never been considered the primary culprits of β-cell destruction.
However, this pathway may prove to be the indirect approach to targeting β -cell autoreactivity
[118]. Despite an initial skepticism, some work has been done in this area. Recent studies
performed in an experimental setting reported that depleting B-cells with a short course of
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monoclonal anti-CD20 antibody proved beneficial in abrogating diabetes in young NOD mice,
and significantly delaying the onset of the disease in older animals [119]. A recent clinical trial
conducted by the TrialNet group confirmed these findings by demonstrating that selective and
transient depletion of B-lymphocytes with rituximab, an anti-CD20 monoclonal antibody,
partially preserved β-cell function in patients with recent onset of Type 1 diabetes, for a period
of 1 year [120].
1.4.3. Regulatory R (Treg) cells
Although this cell subset with unique immunomodulatory properties has been briefly
discussed above, these cells deserve special attention and are discussed in more detail in this
section. Ever since the realization that Treg cells have an innate capacity to maintain tolerance
to self-antigens in peripheral organs under immune assault, this population has attracted great
attention with respect to their potential role in the prevention of autoimmune disorders which
include Type 1 diabetes. The interest in these immune traffic regulators peaked when it was
demonstrated that they represented an inducible population able to halt the progression of
IDDM, while curbing autoimmune responses not only to antigens responsible for the induction
of autoimmunity but others involved in this process as well. This represents an attractive
therapeutic alternative for IDDM as to date no specific antigen(s) has been identified as a
causative agent for the diabetogenic response.
As discussed elsewhere in this chapter, autoimmune response aimed at the progressive
destruction of pancreatic β-cells can be manipulated through antigen-based manipulation and
non-antigen-based treatments, possible though the involvement of Treg cell population.
Although immunoregulatory capacity has been demonstrated in several T-cell subsets, the
main players in the field are “natural” CD4+CD25+, and “adaptive or induced” regulatory T-
cells of various phenotypes. “Natural” CD4+CD25+ regulatory T-cells require a variety of co-
stimulatory interactions for their development, and are mainly identified by the FoxP3
transcription factor necessary for the development and function of this cell subset. In vitro,
natural CD4+CD25+ cells have been demonstrated to have an uncanny ability to inhibit T-cell
proliferation and cytokine production, most probably, via cell-cell contact [121]. Despite
previously published dissenting reports, there is an agreement that during the development
of diabetes, the autoreactive T-cell subsets become unresponsive to CD4+CD25+ mediated
suppression mechanism. This could be due to the fact that CD4+CD25+ cell are present in
reduced numbers during the development of the IDDM in humans. At the same time, opposing
results have been obtained in an NOD model: at the time of diabetes onset, CD4+CD25+ cells
exist in equal numbers compared to non-diabetic animals [121]. It’s been also demonstrated
that while CD4+CD25+ cells are relatively abundant in normal individuals, data obtained from
various animal models suggest that antigen-induced Treg cells are present in relatively low
numbers. Despite this fact, of most benefit is the data that demonstrated that once induced,
Treg cells become activated in the immediate tissue where the given autoantigen is expressed.
Of added benefit is the realization that in addition to suppressing the responses of an autoan‐
tigen in question, Treg cells are able to modulate other autoreactive T-cell responses as well,
most probably via production of anti-inflammatory soluble cytokines such as IL-4, IL-10 and
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TGF-β. Pre-clinical studies in non-obese diabetic mice have demonstrated that adoptive
transfer of Tregs can slow diabetes progression and, in some cases, reverse new onset diabetes.
Clinical trials investigating the effect of natural expanded and patient-specific Treg cells on
autoreactive T-cell responses, preservation of β-cell function and other outcomes related to
diabetes management are in progress at the present time [122].
The effect of antigen-based immunotherapy has been discussed earlier in this chapter.
However, to recapitulate, the available data demonstrates that antigen-based immunothera‐
peutics probably favor the induction of immunoregulatory T-cell subsets by reacting with
endogenous reactive autoantigens, and halting the progression of diabetes. In animal models
of IDDM, amplification of Treg cell responses has been achieved using several self-antigens
administered using tolerogenic means such intravenous, intranasal or subcutaneous injection,
or oral feeding. It has also been shown that Treg cells are able to exert their modulatory effector
function through the action of several cytokines, namely IL-4 and IL-10. The situation with
TGF-β is much more complex. When administered as a vaccine, it was shown to confer
protection from diabetes in NOD mice, but not in other animal models [123].
“Adaptive or induced” Treg cells comprise a group of heterogeneous T-cell subsets that arise
as a function of a specific context in which they are generated [120]. These normally go along
with antibody-specific approaches to treating IDDM. For example, treatment with CD3
antibody, a potent treatment option for autoimmune disease, has been associated with a
marked increase in Treg cell populations, although the mode of action was never elucidated
[101,121]. The results of the administration of non-mitogenic anti-CD3 therapy proved to be
encouraging [116]. Recent-onset IDDM patients treated with FcR-nonbinding humanized anti-
CD3 monoclonal antibody were found to maintain their insulin production for ~2 years
following treatment. Although the mechanism of action is well understood, it was thought
that the treatment had a direct effect on pathogenic T-cells and resulted in the induction of
Treg cell population, or both [116,121]. Data from several other clinical trials seems to indicate
that anti-CD3 monotherapy could neither elicit long-term protection, nor protect from adverse
effects. Hence, it is possible that combination of immunotherapeutic options might offer a
better sustained protection against the disease over time.
1.5. Bone Marrow Chimerism
It was Owen, back in 1945, who made an observation that bone marrow cells have the ability
to induce transplantation tolerance to donor histocompatibility antigens. Billingham, Brent
and Medawar confirmed and expanded on this idea by transplanting Major Histocompatibility
Complex (MHC)-disparate bone marrow cells (BMC) into neonatal recipient mice which
resulted in the induction of specific, systemic, stable tolerance to the donor, while preserving
immunocompetence required to reject genetically disparate third party grafts [124]. Fetuses
and neonates, of course, offer an immunoprivileged state, during which pre-conditioning is
not required for the successful BMC engraftment that leads to chimerism. The situation
changes after that. Over the last several decades, numerous investigators working in the area
of bone marrow (BM) conditioning to reduce the immunogenicity of solid and cellular grafts,
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demonstrated that adult recipient pre-conditioning is necessary to “make space” for the
successful engraftment of donor BMC and induction of donor-specific chimerism.
It was initially thought that lethal recipient conditioning which leads to complete BM ablation
was necessary for engraftment of allogeneic BMC. Over time, however, it has become clear
that stable engraftment can be achieved using partial pre-conditioning strategies [125,126].
Conditioning approaches to allow for stable engraftment of donor cells have included total
body irradiation, total lymphoid irradiation, cytoreductive approaches, low dose irradiation
with polyclonal or monoclonal antibodies, single or multiple infusions of large doses of donor
BMC with T-cell co-stimulatory blockade, anti-CD4 and anti-CD8 antibodies with local thymic
irradiation, and targeted BM ablation using bone seeking 153Samarium-Lexidronam (153Sm)
compound with transient T-cell co-stimulatory blockade [125-127]. The fact that hematopoietic
chimerism induces donor-specific tolerance, while preserving third-party reactivity, has been
established in experimental animal models, i.e. rodents [127,128], large animals [129], primates
[130] and in humans [131]. Using conditioning approaches listed above full or mixed chimer‐
ism leading to stable, long-term donor-specific tolerance has been achieved. Although both
full and mixed chimerism can be achieved in animal models, fully chimeric animals demon‐
strate immune-incompetence for antiviral activity and antibody production [125,126]. Mixed
allogeneic chimerism is much more preferable in tolerance induction protocols, as both donor
and recipient antigen presenting cells can be found in the recipient [125].
The realization that BM transplantation represents a credible treatment for diabetes came as a
result of animal studies that demonstrated the interdependence between BMC transplantation
and autoimmune disease: the disease could be transferred from NOD mice to mouse strains
resistant to autoimmunity, while BM from disease-resistant mouse strains could prevent the
development of autoimmunity in NOD mice [125,126]. BMC-associated tolerance to islet cell
grafts has been achieved in a number of animal models and human subjects [125,126,132].
Donor-specific tolerance has been demonstrated in both animals that were first precondi‐
tioned, treated with donor-specific BMC, with the islet graft placed at a later date, and those
that received islet grafts 24-48 hours after BMC infusion [125,126]. Over the last several decades
a profound contribution has been made to the understanding of underlying processes in the
induction of BM-derived tolerance to pancreatic islet grafts in the later stages of diabetes,
prevention of recurrence of autoimmunity in the graft, and reversal of overt diabetes once the
pre-diabetic state is identified [125,126].
Animal Type 1 diabetes models fall into two groups, which deal with etiology of the disease.
Diabetes can be induced chemically or surgically, or developed spontaneously as in BB rat or
NOD mouse model. In the first case autoimmunity is not an underlying factor of the disease.
In the second case, however, the disease progresses spontaneously, similarly to the clinical
course of Type 1 diabetes, which is autoimmune in nature. BMC transfer experiments between
the NOD mouse and disease-resistant mouse strains discussed earlier have suggested that it
is a BMC-derived stem cell that is associated with the development of the autoimmunity
observed in Type 1 diabetes. Both unmodified and T-cell depleted NOD-derived BMC can
transfer autoimmunity followed by diabetes development [125,126]. Conversely, BMC from
diabetes-resistant mouse strains, when transferred to a lethally, or sub-lethally conditioned
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NOD mice and rendering these recipients mixed chimeras, reverses insulitis and the autoim‐
mune process, halting the development of overt diabetes. Ildstad proposed two possible
explanations for how allogeneic BMC-derived chimerism can prevent diabetes. First, donor
BMC activates a regulatory cell instrumental in suppressing the activation of autoreactive
lymphocytes identified as a culprit in the progression of autoimmunity, development of the
overt diabetes and fully developed disease. Second, BMC can cause clonal deletion of autor‐
eactive T lymphocytes via donor-specific disease resistant APCs [126].
Taking into an account that it is a BM stem cell that’s involved in the development of autoim‐
mune disease, the timing of BMC administration for the treatment of autoimmune diabetes is
critical. Due to the fact that autoimmunity results in the progressive destruction of pancreatic
β-cells, the ultimate timing for BMC infusion is during the early stages of the disease, when
overt diabetes ensues, exogenous insulin is administered, and return to normoglycemia and
even production of endogenous insulin are observed. However, the main drawback for the
widespread use of BMC therapy to treat Type 1 diabetes is harsh, often lethal, recipient pre-
conditioning regiments. Although non-lethal conditioning protocols, discussed earlier, have
been developed, donor-specific chimerism reported under such circumstances is often
transient [126]. However, encouraging results in terms of the induction of stable chimerism in
kidney transplant recipients have been recently reported by Leventhal et al [132]. He used
mobilized cells enriched for hematopoietic stem cells (HSC) in combination with a graft-
facilitating cell (FC) population (CD8dim, CD3+/CD45R+/Thy1+/Class IIdim/intermediate, αβ-TCR- and
δλ-TCR-) and nonmyeloablative conditioning in recipients of MHC mismatched, unrelated
kidney grafts. Five out of eight transplant recipients exhibited stable donor-specific chimerism,
and were weaned of immunosuppression at 1 year following transplant. None of the transplant
recipients were reported to show signs of GVHD. As previously reported by Ildstad [125], the
FC is not a stem cell, but this population seems to be necessary to enable successful BMC
engraftment in MHC disparate environment. Although the mechanism by which FC aids
engraftment is not clear, it was characterized previously and found to be necessary to prevent
GVHD and promote engraftment in standard BMC transplant protocols [125,126]. These
results are exciting and offer much optimism towards treatment strategies applicable to
patients with Type 1 diabetes.
Type 1 diabetes is a multifaceted disease, for which no single arm immunotherapeutic
approach is possible. It has been long established that immunotherapies that target early vs.
later pre-clinical stages in the disease progression offer a treatment approach with higher
likelihood of success. However, even that might not be enough to effectively solve this
formidable problem. It is possible that no single immunotherapeutic approach will offer long-
term protection from diabetes onset and progressive autoimmune destruction of β-cells, in
either prevention or treatment setting. A number of immunological approaches, in combina‐
torial manner, that exploit the strengths and circumvent the adverse events of potential
therapies at the same time, might prove to be the answer. At this point such approaches are
still in the development stage, albeit many hurdles have been overcome to move this approach
forward. Latest developments in this area do offer much optimism.
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1.6. Concluding remarks
Cell replacement strategies offer an enormous potential for the treatment of patients with Type
1 diabetes, in both clinical and economic terms. The availability of unlimited amounts of
functionally competent graft material to treat millions of patients suffering from IDDM and
its dreadful, debilitating complications can move this field forward from the experimental
stage it has found itself in for the last several decades to the forefront of transplantation
medicine. The fact that allogeneic islet transplantation offers the most extensively studied and
sensible solution to potential cure for IDDM is clear. However, this therapeutic option is far
from a perfect solution, and comes hand-in-hand with several problems in the form of serious
shortages of the available organs and resulting tissue to satisfy the ever-growing demand,
recurrence of autoimmunity and rejection and life-long immunosuppression. Porcine islets
offer a viable substitution or addition to the allogeneic islet therapy, offering both a function‐
ally competent adult cell source with already developed insulin-sensing machinery, and
sufficient quantities of tissue immediately available for transplant. However, before persistent
problems with immune rejection and destruction of the graft can be overcome, porcine islets
do not have a hope of replacing or supplementing allogeneic islet cells as a viable treatment
option. Embryonic stem cells have the required proliferative potential, with recent studies
clearly demonstrating that ESCs provide a definitive platform for differentiation into insulin
producing structures. However, it remains to be seen whether (a) current experimental
protocols can be scaled-up to generate sufficient number of cells for transplant; (b) current
purification methods offer sufficiently stringent protocols to be able to transplant glucose-
sensing β-like cells only, all the while unequivocally excluding potentially oncogenic “other
types” of cell populations; (c) functional equivalency of the resulting glucose-sensing β-like
cells to native β-cells can be clearly confirmed; and (d) the cell graft can be adequately protected
to avoid efficient immune surveillance systems of the host. This is where the concept of
generating sufficient insulin-producing tissue from an autologous, i.e. patient-specific, source
becomes attractive. However, the early promise of this iPSCs has not translated from it early
success in the experimental setting to the clinical model, mostly due to the same problems that
are associated with ESCs. These, however, are multiplied by the limited proliferative capacity
of these cells, as well as issues with inadequate function, i.e. poor insulin expression coupled
with very low insulin secretion. The problems that stem from immunogenicity of the graft
tissue are intrinsic to cells from various sources, including a tailored patient-specific iPSCs-
derived approach. With the number of factors impacting the way β-cell autoimmunity can be
manipulated, several key issues might be considered when it comes to the development of
immunotherapeutic solutions to diabetes. These include the requirement for the suppression
of the diabetogenic response early in the course of the development of the disease, as well as
clear understanding of the autoreactive antigen(s) that might be defined by particular geno‐
type and/or environmental exposure. The complexity of IDDM means that immunomodula‐
tory therapies, antigen- and antibody-specific, might offer a solution when utilized in
combination. The goal here is to preserve the functional capacity of the cellular graft or innate
islet cells, while at the same time attempting to restore the unique balance between the
pathogenic effector and the immunomodulatory T-cell population eroded by the autoimmune
assault brought forth by the onset of the disease. Combination immunotherapy will likely
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prove the most effective by exploring the strength of each approach, while limiting the adverse
effects associated with each. Despite significant success attained in this area, most progress so
far has been made in experimental models, while clinical applications are still relatively early
in their development. Although the challenge of bench-to-bedside technology transfer is
significant, success of the last few years give much hope and even optimism for future clinical
developments.
Various types of cellular therapies discussed in this chapter might offer multi-faceted and
practical approaches to the treatment of diabetes. It is entirely possible that a choice of several
different therapeutic options is of great benefit, and might provide a platform to avoid
frustrating developmental pains towards a “universal cure”. While the prospect of developing
patient-specific, i.e. personalized, cellular therapy is appealing, it is complicated, quite
expensive and, it’s tempting to say, unrealistic to develop. Each of the allogeneic cell replace‐
ment approaches towards a potential therapeutic option discussed here needs to be carefully
studied, dissected, and defined regardless of the costs associated with it. Further development
in the area of immunotherapeutic approaches and various immunoisolation methodologies,
which are beyond the scope of this chapter, will be able to help move cell replacement therapy
to the forefront of transplant science. Given the fact that for almost a century administration
of exogenous insulin was the only real available therapeutic alternative to the treatment of
IDDM, the developments of the past several decades are exiting. It is quite possible that the
following decade will see clinical application of a whole gamut of therapeutic options to treat
this devastating disease.
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